Overview
- Third-quarter net revenue rose 9.1% to $15.78 billion, topping the $15.59 billion consensus.
- Adjusted EPS was $1.86, down 38% year over year but above expectations, while GAAP EPS fell to $0.10 on higher taxes and acquisition-related costs.
- The company said year-to-date acquired IPR&D and milestone expenses reduced results by $2.05 per share and guided with that impact included.
- Immunology drove growth with Skyrizi at $4.71 billion (+46.8%) and Rinvoq at $2.18 billion (+35.3%), offsetting Humira’s decline to $993 million (−55%).
- AbbVie raised full-year adjusted EPS guidance to $10.61–$10.65 and increased its quarterly dividend to $1.73, as the stock fell about 4% after the report.